Kiniksa Pharmaceuticals
Chris Heberlig is the current Chief Financial Officer at Kiniksa Pharmaceuticals. Chris has over 25 years of experience in the finance and accounting industry.
Chris began their career as a Senior Auditor at PricewaterhouseCoopers, where they worked for three years. Chris then transitioned to the corporate world and held various finance positions at NetGenesis, EPIX Pharmaceuticals, Panacos Pharmaceuticals, and Synageva BioPharma. In 2015, they joined Kiniksa Pharmaceuticals as their Executive Vice President and Chief Financial Officer.
In 2020, Heberlig left Kiniksa to start their own consulting firm, 2C Advisory LLC / Danforth Advisors. Chris consulted for various companies until they returned to Kiniksa Pharmaceuticals in December 2021.
Chris Heberlig has a BA in Economics from St. Lawrence University and an MBA from Questrom School of Business at Boston University.
They are on a team with Mark Ragosa - Chief Financial Officer, Mike Megna - VP Finance & Chief Accounting Officer, and Martina Struck - SVP, Regulatory Affairs. Chris Heberlig reports to Sanj K. Patel, CEO & Chairman.
This person is not in any offices
Kiniksa Pharmaceuticals
2 followers
Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.